← boardnext 2026-08next 2027-06
AKBA
Akebia Therapeuticsdistress 0/10 · well-funded / low risk$1.23-3%today-69% from 52w high
Hematology 2
Lead: Anemia of Chronic Kidney Disease · est. market ~$10B (approx, global)
Revenue
$54M
Liquidity
$163M
Runway
—
Shares 1y
+1%
Price & events
-14.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.8%
1D
-12.5%
1W
+11.4%
1M
-14.3%
3M
-9.9%
6M
-69.5%
1Y
-16.1%
2Y
-50.4%
5Y
-58.1%
All
Overview
- Market Cap
- $328.62M
- Enterprise Value
- $202.37M
- Volume
- 148.35K
- 52 Week Range
- $0.87 – $4.01
- Total Shares
- 268.26M
- Float Shares
- 262.01M
- Short %
- 7.26%
- % Held by Insiders
- 4.06%
- % Held by Institutions
- 42.10%
- RVOL
- 0.03x
- Beta
- 0.23
Pipeline stages · 3 programs
Erythropoiesis-Stimulating Agent (ESA), Vadadustat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Praliciguat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
vadadustat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | Erythropoiesis-Stimulating Agent (ESA), Vadadustat | Anemia of Chronic Kidney Disease | — | active not recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | Praliciguat | Focal Segmental Glomerulosclerosis | — | recruiting |
| 2026-07 | Phase 3 | vadadustat | Anemia of Chronic Kidney Disease | 0 | withdrawn |
| 2026-07 | Phase 3 | Vadadustat | Anemia of Chronic Kidney Disease | 0 | withdrawn |
Catalyst news & presentations · 5
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-11-28partnershipADX-097 (AKB-097) · Acquired from Q32 Bio for $10M upfront plus up to $582M in milestones and royalties.SEC 8-K
- 2025-10-28trial discontinuedvadadustat · Company cancels VALOR trial for vadadustat in CKD anemia after failing to align with FDA on trial design.SEC 8-K
- January 16, 2025 at 7:30 a.m. PSTconferencedata presentationsecondaryCEO presentation at 43rd Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- 2024-10-22partnershipVafseo · Multi-year commercial supply agreement with leading dialysis organization for patients on dialysisSEC 8-K
Approved drugs (1)
- VAFSEOVADADUSTAT2024 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $4 (+243% upside) · 5 analysts
- 2026-07-01HC Wainwright & Co.Buy
- 2026-04-07BTIGBuy
- 2026-02-25BTIGBuy
- 2026-02-06HC Wainwright & Co.Buy
- 2026-02-06Piper SandlerOverweight
- 2025-12-02BTIGBuy
Competitors — Anemia of Chronic Kidney Disease
- IRONDisc Medicine, Inc.$2.8B · D1
Recent news
- 2026-07-22Akebia Therapeutics (AKBA) Q2 2024 earnings summary - Quartr
- 2026-07-21Lobbying Update: $360,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
- 2026-07-21AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
- 2026-07-17Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Declines By 34.3% - MarketBeat
- 2026-07-17Akebia Therapeutics (NASDAQ:AKBA) Shares Pass Above Fifty Day Moving Average - Here's What Happened - MarketBeat
- 2026-07-14Lobbying Update: $60,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
- 2026-07-14Akebia: Vafseo Gains Traction, But It’s Still A Show-Me Story (Rating Downgrade) (AKBA) - Seeking Alpha
- 2026-07-14Lobbying Update: $60,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.